Chlamydia in pregnancy

A randomized trial of azithromycin and erythromycin

Charles Adair, Marc Gunter, Thomas G. Stovall, Gayle McElroy, Jean Claude Veille, Joseph M. Ernest

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Objective. To determine side effect profiles and cure rates of azithromycin compared with erythromycin in the treatment of chlamydial cervicitis complicating pregnancy. Methods: Pregnant patients with positive DNA antigen assays for Chlamydia trachomatis were randomized to either azithromycin, 1 g oral slurry in a single dose, or erythromycin, 500 mg every 6 hours for 7 days. Repeat assays were planned for 3 weeks after therapy. Side effects, compliance, and treatment efficacy were assessed. Results: One hundred six women were enrolled, and eighty-five women completed the protocol. Significantly fewer gastrointestinal side effects were noted in the azithromycin group than in the erythromycin group (11.9% versus 58.1%, P ≤ .01). Enhanced compliance was noted with azithromycin, because it was given in a single observed dose. Similar treatment efficacy was noted between azithromycin and erythromycin (88.1% versus 93.0%, P > .05). Conclusion: Compared with erythromycin, azithromycin is associated with significantly fewer gastrointestinal side effects in pregnancy. This association, along with the ease of administration and similar efficacy, suggests that azithromycin should be considered for the initial treatment of chlamydial cervicitis in pregnancy.

Original languageEnglish (US)
Pages (from-to)165-168
Number of pages4
JournalObstetrics and Gynecology
Volume91
Issue number2
DOIs
StatePublished - Feb 1 1998
Externally publishedYes

Fingerprint

Azithromycin
Chlamydia
Erythromycin
Pregnancy
Uterine Cervicitis
Compliance
Chlamydia trachomatis
Therapeutics
Antigens
DNA

All Science Journal Classification (ASJC) codes

  • Obstetrics and Gynecology

Cite this

Chlamydia in pregnancy : A randomized trial of azithromycin and erythromycin. / Adair, Charles; Gunter, Marc; Stovall, Thomas G.; McElroy, Gayle; Veille, Jean Claude; Ernest, Joseph M.

In: Obstetrics and Gynecology, Vol. 91, No. 2, 01.02.1998, p. 165-168.

Research output: Contribution to journalArticle

Adair, C, Gunter, M, Stovall, TG, McElroy, G, Veille, JC & Ernest, JM 1998, 'Chlamydia in pregnancy: A randomized trial of azithromycin and erythromycin', Obstetrics and Gynecology, vol. 91, no. 2, pp. 165-168. https://doi.org/10.1016/S0029-7844(97)00586-3
Adair, Charles ; Gunter, Marc ; Stovall, Thomas G. ; McElroy, Gayle ; Veille, Jean Claude ; Ernest, Joseph M. / Chlamydia in pregnancy : A randomized trial of azithromycin and erythromycin. In: Obstetrics and Gynecology. 1998 ; Vol. 91, No. 2. pp. 165-168.
@article{e668dc11bda348669a90d8b8f90cf6b0,
title = "Chlamydia in pregnancy: A randomized trial of azithromycin and erythromycin",
abstract = "Objective. To determine side effect profiles and cure rates of azithromycin compared with erythromycin in the treatment of chlamydial cervicitis complicating pregnancy. Methods: Pregnant patients with positive DNA antigen assays for Chlamydia trachomatis were randomized to either azithromycin, 1 g oral slurry in a single dose, or erythromycin, 500 mg every 6 hours for 7 days. Repeat assays were planned for 3 weeks after therapy. Side effects, compliance, and treatment efficacy were assessed. Results: One hundred six women were enrolled, and eighty-five women completed the protocol. Significantly fewer gastrointestinal side effects were noted in the azithromycin group than in the erythromycin group (11.9{\%} versus 58.1{\%}, P ≤ .01). Enhanced compliance was noted with azithromycin, because it was given in a single observed dose. Similar treatment efficacy was noted between azithromycin and erythromycin (88.1{\%} versus 93.0{\%}, P > .05). Conclusion: Compared with erythromycin, azithromycin is associated with significantly fewer gastrointestinal side effects in pregnancy. This association, along with the ease of administration and similar efficacy, suggests that azithromycin should be considered for the initial treatment of chlamydial cervicitis in pregnancy.",
author = "Charles Adair and Marc Gunter and Stovall, {Thomas G.} and Gayle McElroy and Veille, {Jean Claude} and Ernest, {Joseph M.}",
year = "1998",
month = "2",
day = "1",
doi = "10.1016/S0029-7844(97)00586-3",
language = "English (US)",
volume = "91",
pages = "165--168",
journal = "Obstetrics and Gynecology",
issn = "0029-7844",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Chlamydia in pregnancy

T2 - A randomized trial of azithromycin and erythromycin

AU - Adair, Charles

AU - Gunter, Marc

AU - Stovall, Thomas G.

AU - McElroy, Gayle

AU - Veille, Jean Claude

AU - Ernest, Joseph M.

PY - 1998/2/1

Y1 - 1998/2/1

N2 - Objective. To determine side effect profiles and cure rates of azithromycin compared with erythromycin in the treatment of chlamydial cervicitis complicating pregnancy. Methods: Pregnant patients with positive DNA antigen assays for Chlamydia trachomatis were randomized to either azithromycin, 1 g oral slurry in a single dose, or erythromycin, 500 mg every 6 hours for 7 days. Repeat assays were planned for 3 weeks after therapy. Side effects, compliance, and treatment efficacy were assessed. Results: One hundred six women were enrolled, and eighty-five women completed the protocol. Significantly fewer gastrointestinal side effects were noted in the azithromycin group than in the erythromycin group (11.9% versus 58.1%, P ≤ .01). Enhanced compliance was noted with azithromycin, because it was given in a single observed dose. Similar treatment efficacy was noted between azithromycin and erythromycin (88.1% versus 93.0%, P > .05). Conclusion: Compared with erythromycin, azithromycin is associated with significantly fewer gastrointestinal side effects in pregnancy. This association, along with the ease of administration and similar efficacy, suggests that azithromycin should be considered for the initial treatment of chlamydial cervicitis in pregnancy.

AB - Objective. To determine side effect profiles and cure rates of azithromycin compared with erythromycin in the treatment of chlamydial cervicitis complicating pregnancy. Methods: Pregnant patients with positive DNA antigen assays for Chlamydia trachomatis were randomized to either azithromycin, 1 g oral slurry in a single dose, or erythromycin, 500 mg every 6 hours for 7 days. Repeat assays were planned for 3 weeks after therapy. Side effects, compliance, and treatment efficacy were assessed. Results: One hundred six women were enrolled, and eighty-five women completed the protocol. Significantly fewer gastrointestinal side effects were noted in the azithromycin group than in the erythromycin group (11.9% versus 58.1%, P ≤ .01). Enhanced compliance was noted with azithromycin, because it was given in a single observed dose. Similar treatment efficacy was noted between azithromycin and erythromycin (88.1% versus 93.0%, P > .05). Conclusion: Compared with erythromycin, azithromycin is associated with significantly fewer gastrointestinal side effects in pregnancy. This association, along with the ease of administration and similar efficacy, suggests that azithromycin should be considered for the initial treatment of chlamydial cervicitis in pregnancy.

UR - http://www.scopus.com/inward/record.url?scp=0032006580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032006580&partnerID=8YFLogxK

U2 - 10.1016/S0029-7844(97)00586-3

DO - 10.1016/S0029-7844(97)00586-3

M3 - Article

VL - 91

SP - 165

EP - 168

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

SN - 0029-7844

IS - 2

ER -